KIMS to meet with 360One Capital (B&K Securities) on Dec 17, 2025
Krishna Institute of Medical Sciences Limited will hold a group meeting with 360One Capital (B&K Securities) on December 17, 2025, in Hyderabad. No Unpublished Price Sensitive Information will be shared during the meeting.
This is a standard disclosure regarding an upcoming investor meeting. As no Unpublished Price Sensitive Information will be shared, the immediate impact on the company's stock is expected to be minimal.
The announcement is a routine intimation of an investor meeting and does not contain any new financial information or material developments that would impact the company's stock price positively or negatively.
Krishna Institute of Medical Sciences Limited (KIMS) has announced an upcoming meeting with institutional investors. The meeting is scheduled to take place on December 17, 2025, in Hyderabad, India.
The meeting will be with 360One Capital (B&K Securities) and will be a group meeting. KIMS has stated that the schedule is subject to change due to exigencies.
Importantly, no Unpublished Price Sensitive Information (UPSI) will be shared during this meeting.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.